TP53 and leukemia: Due to the relatively low frequency of p53 mutations in acute promyelocytic leukemia (APL, the leukemia subtype approved for ATO treatment) and non-APL leukemia, as well as the limited number of the currently reported ATO-treated solid-tumor patients, we failed to identify ATO-treated patients with known p53 mutational status, except the patient21 that has been analyzed in Figures 5J–5M.